Oranje Bob, Kahn René S, Kemner Chantal, Verbaten Marinus N
Department of Psychopharmacology, Faculty of Pharmaceutical Sciences, Rudolf Magnus Institute for Neurosciences, Utrecht University, Utrecht, The Netherlands.
Psychiatry Res. 2004 Jul 15;127(3):195-205. doi: 10.1016/j.psychres.2004.04.002.
In schizophrenia both an involvement of a reduced prefrontal dopaminergic activity and an enhanced noradrenergic activity have been suggested. In addition, patients suffering from schizophrenia show reduced sensorimotor gating and reduced habituation. If there is a causality between these neurotransmitters and these processes, then either a reduction in dopaminergic activity or an enhanced noradrenergic activity in healthy volunteers would result in reduced sensorimotor gating and reduced habituation. In the present study, a group of 12 healthy male volunteers was tested four times in a prepulse inhibition (PPI) paradigm 2.5 h following administration of placebo/placebo, placebo/desipramine (50 mg), placebo/haloperidol (2 mg) and desipramine (50 mg)/haloperidol (2 mg). A significant reduction of percentage PPI was found in all active treatments compared with placebo/placebo, while no treatment effects on habituation were found. Furthermore, a significant increase in heart rate was found in both desipramine treatments, from 120 min following oral intake onwards. Both desipramine and haloperidol reduced PPI, which suggests that an enhanced noradrenergic activity and a reduced dopaminergic activity lead to a reduction in sensorimotor gating. Since reduced sensorimotor gating is found in schizophrenia, these results supply further evidence for a reduced prefrontal dopaminergic activity and an enhanced noradrenergic activity in schizophrenia. Furthermore, the combination of haloperidol and desipramine did not have a synergistic effect on PPI, which indicates an interaction between the compounds. The site for this interaction is most likely located in the prefrontal cortex, since evidence is accumulating that extracellular dopamine concentration is regulated by noradrenergic terminals, particularly in the frontal areas of the brain. Since no effects on habituation were found, this suggests that neither enhanced noradrenergic nor decreased dopaminergic activity is involved in this process.
精神分裂症患者中,有人提出存在前额叶多巴胺能活性降低和去甲肾上腺素能活性增强的情况。此外,精神分裂症患者表现出感觉运动门控降低和习惯化减弱。如果这些神经递质与这些过程之间存在因果关系,那么健康志愿者中多巴胺能活性降低或去甲肾上腺素能活性增强都会导致感觉运动门控降低和习惯化减弱。在本研究中,一组12名健康男性志愿者在服用安慰剂/安慰剂、安慰剂/地昔帕明(50毫克)、安慰剂/氟哌啶醇(2毫克)和地昔帕明(50毫克)/氟哌啶醇(2毫克)后2.5小时,在预脉冲抑制(PPI)范式下接受了四次测试。与安慰剂/安慰剂相比,所有活性治疗的PPI百分比均显著降低,而未发现对习惯化有治疗效果。此外,两种地昔帕明治疗均发现心率显著增加,从口服后120分钟开始。地昔帕明和氟哌啶醇均降低了PPI,这表明去甲肾上腺素能活性增强和多巴胺能活性降低会导致感觉运动门控降低。由于精神分裂症患者存在感觉运动门控降低的情况,这些结果进一步证明了精神分裂症患者前额叶多巴胺能活性降低和去甲肾上腺素能活性增强。此外,氟哌啶醇和地昔帕明的组合对PPI没有协同作用,这表明这些化合物之间存在相互作用。这种相互作用的位点很可能位于前额叶皮层,因为越来越多的证据表明细胞外多巴胺浓度受去甲肾上腺素能终末调节,特别是在大脑的额叶区域。由于未发现对习惯化有影响,这表明去甲肾上腺素能增强或多巴胺能降低均不参与此过程。